Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.37 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.37 |
| ▸ | DRD2 | P14416 | 5/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | ATF4 | P18848 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23149238 | 0.85 | KMT2A (0.41) | MEN1KMT2AALDH1A1GAAMAPT | |
| SCHEMBL29435970 | 0.73 | DPP9 (0.44) | DPP8DPP9DRD2MEN1KMT2A | |
| SCHEMBL5731619 | 0.72 | POLB (0.54) | MEN1KMT2AALDH1A1GAAMAPT | |
| SCHEMBL6233789 | 0.70 | GAA (0.54) | MEN1KMT2AALDH1A1GAAMAPT | |
| SCHEMBL29525089 | 0.69 | DRD2 (0.47) | DPP8DPP9DRD2MEN1KMT2A | |
| SCHEMBL16118673 | 0.68 | MEN1 (0.46) | DPP8DPP9MEN1KMT2AGAA | |
| SCHEMBL23332808 | 0.68 | ATF4 (0.76) | MEN1KMT2AALDH1A1TSHRATF4 | |
| SCHEMBL29684191 | 0.67 | KMT2A (0.43) | MEN1KMT2AIDO1ALDH1A1GAA | |
| SCHEMBL23149113 | 0.67 | ATF4 (0.43) | MEN1KMT2AALDH1A1GAAMAPT | |
| SCHEMBL20884878 | 0.66 | BRD4 (0.45) | IDO1MAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210093619-A1 | Chemical Compounds as ATF-4 Pathway Inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210093619-A1 | Chemical Compounds as ATF-4 Pathway Inhibitors | ATF4, ATF1, XBP1 | DPP8 1222/4885DPP9 1744/4885DRD2 1654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.